| Movement Med, Llc | |
|
1317 State Highway 102 Ste B Bar Harbor ME 04609-7018 | |
| (207) 801-9277 | |
| (207) 801-9289 |
| Full Name | Movement Med, Llc |
|---|---|
| Speciality | Clinic/Center |
| Location | 1317 State Highway 102, Bar Harbor, Maine |
| Authorized Official Name and Position | Joel David Chaloux (CHIROPRACTOR/MANAGER) |
| Authorized Official Contact | 2035259904 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Movement Med, Llc 1317 State Highway 102 Ste B Bar Harbor ME 04609-7018 Ph: (207) 801-9277 | Movement Med, Llc 1317 State Highway 102 Ste B Bar Harbor ME 04609-7018 Ph: (207) 801-9277 |
| NPI Number | 1548843261 |
|---|---|
| Provider Enumeration Date | 04/30/2021 |
| Last Update Date | 06/04/2021 |
| Medicare PECOS PAC ID | 3577962711 |
|---|---|
| Medicare Enrollment ID | O20210520001716 |
News Archive
"The World Health Organization reports Guinea worm disease, which has plagued people for thousands of years, is on the verge of eradication," VOA News reports. "The U.N. agency says fewer than 400 cases of the infectious parasitic disease exist in four African countries, and that it will soon become only the second, after smallpox, to be wiped off the face of the earth," the news service writes.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society in Denver, Colorado.
A group of scientists led by Professor Xavier Pares of the Department of Biochemistry and Molecular Biology at Universitat Autonoma de Barcelona, has published a research on AKR1B10, an enzyme that is detected in large quantities only in lung cancers, particularly those caused by smoking.
Repros Therapeutics Inc. today reported it has received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal® in men with secondary hypogonadism. The Company has submitted the protocol for FDA comment and plans to begin enrolling subjects in January. Depending on the rate of subject enrollment, Repros hopes to have the study completed before the end of 2011.
When cells are attacked by bacteria they use all means at their disposal to defend themselves. But cellular defence systems can damage the cells themselves and so need to be kept tightly in check. Recent results help us to understand how this is done and give pointers to new ways of combating disease. Matthias Farlik in the group of Thomas Decker at the Centre for Molecular Biology of the University of Vienna (Max F. Perutz Laboratories) and Mathias Müller of the University of Veterinary Medicine, Vienna have published these findings in the current issue of the journal "Immunity".
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548843261 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| Provider Name | Joel David Chaloux |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1437719812 PECOS PAC ID: 1759611031 Enrollment ID: I20190930002051 |
News Archive
"The World Health Organization reports Guinea worm disease, which has plagued people for thousands of years, is on the verge of eradication," VOA News reports. "The U.N. agency says fewer than 400 cases of the infectious parasitic disease exist in four African countries, and that it will soon become only the second, after smallpox, to be wiped off the face of the earth," the news service writes.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society in Denver, Colorado.
A group of scientists led by Professor Xavier Pares of the Department of Biochemistry and Molecular Biology at Universitat Autonoma de Barcelona, has published a research on AKR1B10, an enzyme that is detected in large quantities only in lung cancers, particularly those caused by smoking.
Repros Therapeutics Inc. today reported it has received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal® in men with secondary hypogonadism. The Company has submitted the protocol for FDA comment and plans to begin enrolling subjects in January. Depending on the rate of subject enrollment, Repros hopes to have the study completed before the end of 2011.
When cells are attacked by bacteria they use all means at their disposal to defend themselves. But cellular defence systems can damage the cells themselves and so need to be kept tightly in check. Recent results help us to understand how this is done and give pointers to new ways of combating disease. Matthias Farlik in the group of Thomas Decker at the Centre for Molecular Biology of the University of Vienna (Max F. Perutz Laboratories) and Mathias Müller of the University of Veterinary Medicine, Vienna have published these findings in the current issue of the journal "Immunity".
› Verified 3 days ago
News Archive
"The World Health Organization reports Guinea worm disease, which has plagued people for thousands of years, is on the verge of eradication," VOA News reports. "The U.N. agency says fewer than 400 cases of the infectious parasitic disease exist in four African countries, and that it will soon become only the second, after smallpox, to be wiped off the face of the earth," the news service writes.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society in Denver, Colorado.
A group of scientists led by Professor Xavier Pares of the Department of Biochemistry and Molecular Biology at Universitat Autonoma de Barcelona, has published a research on AKR1B10, an enzyme that is detected in large quantities only in lung cancers, particularly those caused by smoking.
Repros Therapeutics Inc. today reported it has received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal® in men with secondary hypogonadism. The Company has submitted the protocol for FDA comment and plans to begin enrolling subjects in January. Depending on the rate of subject enrollment, Repros hopes to have the study completed before the end of 2011.
When cells are attacked by bacteria they use all means at their disposal to defend themselves. But cellular defence systems can damage the cells themselves and so need to be kept tightly in check. Recent results help us to understand how this is done and give pointers to new ways of combating disease. Matthias Farlik in the group of Thomas Decker at the Centre for Molecular Biology of the University of Vienna (Max F. Perutz Laboratories) and Mathias Müller of the University of Veterinary Medicine, Vienna have published these findings in the current issue of the journal "Immunity".
› Verified 3 days ago
Gerrish Chiropractic Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 276 State Highway 3, Bar Harbor, ME 04609 Phone: 207-288-3980 Fax: 207-288-8030 | |
Bar Harbor Family Medicine, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 333 Main St, Bar Harbor, ME 04609 Phone: 503-863-6868 Fax: 207-506-5727 |